Infliximab ( Remicade ) is a monoclonal antibody against TNFα. It is used to treat autoimmune diseases. Remicade is marketed by Centocor in the USA, Mitsubishi Tanabe Pharma in Japan, Xian Janssen in China, and Schering-Plough elsewhere.
Infliximab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. Infliximab (Remicade) won its initial approval by the FDA for the treatment of Crohn's disease in August 1998.
Infliximab works by binding to tumour necrosis factor alpha (TNFα). TNFα is a chemical messenger (cytokine) and a key part of the autoimmune reaction. Originally, it was assumed that Infliximab works by blocking the action of TNFα by preventing it from binding to its receptor in the cell, and for the action of infliximab in rheumatoid arthritis this still seems to be true. Another TNFα-neutralizing medication,however, Enbrel is worse than a placebo in Crohn's disease and thus TNFα-neutralisation is not responsible for its powerful action in the latter disease. As infliximab causes programmed cell death of TNFα-expressing activated T lymphocytes, an important cell type mediating inflammation, but Enbrel does not have this activity, now it is generally assumed that resolution of activated T cells by Infliximab explains its efficacy in Crohn's disease.
Inflixmab is an artificial antibody. It was originally developed in mice, as a mouse antibody. Because humans have immune reactions to mouse proteins, it was later developed into a human (humanized) antibody. Because the antibodies were produced from one cell that was grown into a clone of identical cells, it is called a monoclonal antibody. Because it is a combination of mouse and human antibody, it is called a chimeric monoclonal antibody.
Infliximab was developed by Junming Le and Jan Vilcek at New York University School of Medicine and developed by Centocor, a biotechnology company later purchased by Johnson & Johnson.
Infliximab can cost $19,000 to $22,000 a year per patient wholesale, according to Centocor.
Other monoclonal antibodies targeting TNFα are golimumab (Simponi), adalimumab (Humira), and certolizumab pegol (Cimzia). Etanercept ( Enbrel ) also binds and inhibits the action of TNFα but is not, strictly speaking, a monoclonal antibody (it is instead a fusion of TNF-receptor and an antibody constant region).
Infliximab (Remicade) is administered by intravenous infusion, typically at 6-8 week intervals, and at a clinic or hospital. It cannot be administered orally, because the digestive system would destroy the drug.
Pharmacology
According to product labeling, Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble (free floating in the blood) and transmembrane (located on the outer membranes of T cells and similar immune cells) forms of TNFα and inhibits or prevents the effective binding of TNFα with its receptors. Infliximab (Remicade) and Humira (another TNF antagonist) are in the subclass of "anti-TNF antibodies" (they are in the form of naturally occurring antibodies), and are capable of neutralizing all forms (extracellular, transmembrane, and receptor-bound) of TNF alpha. Enbrel, a third TNF antagonist, is in a different subclass (receptor-construct fusion protein), and, because of its modified form, cannot neutralize receptor-bound TNFa. Additionally, the anti-TNF antibodies Humira and infliximab (Remicade) have the capability of lysing cells involved in the inflammatory process, whereas the receptor fusion protein apparently lacks this capability. Although the clinical significance of these differences have not been absolutely proven, they may account for the differential actions of these drugs in both efficacy and side effects.
Infliximab has high specificity for TNFα, and does not neutralize TNF beta (TNFβ, also called lymphotoxin α), an unrelated cytokine that uses different receptors from TNFα. Biological activities that are attributed to TNFα include: induction of proinflammatory cytokines such as interleukin (IL) 1 and IL 6, enhancement of leukocyte movement or migration from the blood vessels into the tissues by increasing the permeability of endothelial layer of blood vessels; and increasing the release of adhesion molecules. Infliximab prevents disease in transgenic mice (a special type of mice that are biologically engineered to produce a human form of TNFα and which are used to test the results of these drugs that might be expected in humans). These experimental mice develop arthritis as a result of their production of human TNFα, and when administered after disease onset, infliximab allows eroded joints to heal.
Infliximab in Crohn's disease
There are three phenotypes, or categories of disease presentation in Crohn's disease: stricturing disease (which causes narrowing of the bowel), penetrating disease (which causes fistulae or abnormal connections of the bowel), and inflammatory disease (which causes primarily inflammation).
Fistulizing disease
Infliximab was first used for closure of fistulae in Crohn's disease in 1999. In a 94-patient phase II clinical trial, the researchers showed that Infliximab was effective in closing fistulae between the skin and bowel in 56-68% of patients. A large 296-patient Phase III clinical trial called the ACCENT 2 trial, showed that infliximab was additionally beneficial in maintaining closure of fistulae, with almost two-thirds of all patients treated with the 3 initial doses infliximab (Remicade) having a fistula response after 14 weeks, and 36% of patients maintaining closure of fistulae after a year, compared with 19% who received placebo therapy. This final trial resulted in the FDA approval of the drug to treat fistulizing disease.
Inflammatory disease
Infliximab has also been used in order to induce and maintain remission in inflammatory Crohn's disease. The ACCENT 1 trial was a large multicentre trial that showed that 39 to 45% of patients treated with infliximab who had an initial response to it, maintained remission after 30 weeks, compared with 21% who received placebo treatment. It also showed a mean maintenance of remission from 38 to 54 weeks compared with 21 weeks for patients who received placebo treatment.
Crohn's patients have flares of their disease between periods of disease quiescence. Severe flares are usually treated with steroid medications to obtain remission, but steroids have many undesirable side effects, and therefore some gastroenterologists are now advocating for the use of infliximab as the first drug to try to get patients into remission. This has been called the top-down approach to treatment.
Infliximab in ulcerative colitis
Infliximab targets TNF, thought to be more related to Th1 cytokines. Ulcerative colitis was thought to be a Th2 disease, and Infliximab of limited use. However, patients with ulcerative colitis have begun to be treated with infliximab on the basis of two large clinical trials conducted in 2005 by Paul Rutgeerts and William Sandborn. The ACT 1 and ACT 2 (Acute ulcerative Colitis Treatment) trials evaluated the utility of infliximab in ulcerative colitis and showed that 44-45% of patients treated with infliximab for a year maintained a response to the medication, compared with 21% of patients who were treated with placebo medication. At 2 months, the response was 61-69% for patients treated with infliximab, and 31% for those who were treated with placebo.
Safety
According to the product labeling of infliximab, etanercept, and adalimumab, these drugs are in the class of immunosuppressants. A number of studies and reports of adverse and serious adverse reactions in patients receiving infliximab have been conducted. Risks include:
- serious and sometimes fatal blood disorders
- serious infections
- lymphoma and solid tissue cancers
- reports of serious liver injury
- reactivation of hepatitis B
- reactivation of tuberculosis
- lethal hepatosplenic T-cell lymphoma
- drug induced lupus
- demyelinating central nervous system disorders
Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported with infliximab. The FDA issued a warning to doctors appearing in the respective product labeling of infliximab instructing them to screen and monitor potential patients more carefully. The FDA issued a warning to doctors that there is an increased risk of lymphoma and other cancers associated with the use of infliximab and other tumor necrosis factor (TNF) blockers in children and adolescents.
Maintenance therapy with the drug (versus intermittent or sporadic therapy) lessens the likelihood of developing antibodies to infliximab which are known to reduce the efficacy of the drug. Combination treatment with methotrexate (an anti-folate drug which suppresses the immune system) has been shown to reduce the formation of these antibodies in patients with rheumatoid arthritis and combination therapy with other immunosuppressants has been shown to reduce the likelihood of these antibodies being formed in Crohn's disease. The use of immunosuppressants may not be necessary in all diseases for which infliximab is indicated, and indiscriminant use of th
Data.gov - Child-Related Product Recalls
Child-Related Product Recalls ... US Consumer Product Safety Commission: Sub-Agency: Category: Wholesale and Retail Trade
Cutting Edge Products [Wholesale Child Safety]
Check out our line of wholesale child safety products like our Balcony Guard. At Cutting Edge Products, we help you protect your family.
Cutting Edge Products [Wholesale Safety Products]
Ebay Product Lister Start a ... See our line of wholesale safety products including safety lights ... Child Finder Fire Rescue Decal with Suction Cup
Infant/Children Product Recalls (not including toys)
Burley Design Recalls Child Trailers Due to Risk of Injury ... Dorel Juvenile Group Expands Recall of Safety 1st Stair ... and Bracelet Sets Recalled by D&D Distributing-Wholesale Due ...
Governor Rell: In Ceremony, Governor Rell Signs Child Product Safety ...
Child Product Safety Bill In a ceremony at a New Britain toy ... develop a certificate of disposition for retailers and wholesalers to account for any children's product ...
CHILD SAFETY PRODUCTS & BABY GEAR STORE by My Precious Kid®
Wholesale; FREE CATALOG - Email your name & USA address or CATALOG ... We are happy to help you select the right safety product for your special needs child.
CHILD SAFETY PACK - Child Safety ID DNA Fingerprint at MyPreciousKid ...
Wholesale; FREE CATALOG - Email your name & USA address or CATALOG download ... Each card in this child safety product holds child’s photo, thumbprint, name, address, weigh ...
AN ACT CONCERNING CHILD PRODUCT SAFETY
AN ACT CONCERNING CHILD PRODUCT SAFETY ... The act subjects retailers or wholesalers to the penalties of the State Child Protection Act, as amended ...
SUBJECT: Child Product Safety.
... LS 6435 NOTE PREPARED: Jan 9, 2008 BILL NUMBER: SB 348 BILL AMENDED: SUBJECT: Child Product Safety ... manufacturing, remanufacturing, retrofitting, distributing, selling at wholesale or ...
AN ACT CONCERNING CHILD PRODUCT SAFETY.
AN ACT CONCERNING CHILD PRODUCT SAFETY. ... banned hazardous substance; (2) the manufacturing, distributing, selling at wholesale ...